Industry News

Biotechnology Industry News

Boehringer Ingelheim’s busy year…

October 31st, 2025|FierceBiotech|

Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody.

Rich Segal highlights the…

October 31st, 2025|FierceBiotech|

Rich Segal highlights the importance of early IPO preparation for companies in the biotech sector and underscores how Chinese biotech companies are increasingly shaping the global biotech landscape.

4DMT has sold the Asia-Pacific…

October 31st, 2025|FierceBiotech|

4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 million in cash to fund the asset’s phase 3 development.

Gilead has chosen a partner for…

October 30th, 2025|FierceBiotech|

Gilead has chosen a partner for lenacapavir in the race to develop low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma has elected to pair GS-3242 with

Steven Hatfill, a senior advisor…

October 30th, 2025|FierceBiotech|

Steven Hatfill, a senior advisor for biosecurity at the Department of Health and Human Services, has been terminated from HHS “for cause,” an agency spokesperson confirmed to Fierce Biotech.

Eli Lilly has halted development…

October 30th, 2025|FierceBiotech|

Eli Lilly has halted development of a phase 2 P2X7 inhibitor for pain in the latest shakeup to a pipeline that has already seen significant pivots this year.

Bristol Myers Squibb is shedding…

October 30th, 2025|FierceBiotech|

Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.

Inflammation biotech Evommune…

October 30th, 2025|FierceBiotech|

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.

Sensei Biotherapeutics is…

October 30th, 2025|FierceBiotech|

Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning of imminent layoffs as the company mulls its options.

After Intellia Therapeutics paused…

October 30th, 2025|FierceBiotech|

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the FDA has made things official by placing the studies under a clinical hold.

Roche has headed back to China to…

October 30th, 2025|FierceBiotech|

Roche has headed back to China to pen a licensing deal worth more than $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases.

Roche’s Genentech unit is laying…

October 29th, 2025|FierceBiotech|

Roche’s Genentech unit is laying off staff at its Bay Area headquarters for the third time this year, saying goodbye to 118 employees in a workforce reduction that spans multiple departments.

SVP David Burnham outlines how…

October 29th, 2025|FierceBiotech|

SVP David Burnham outlines how payer engagement, digital innovation and patient-centric design are reshaping clinical trials and accelerating development timelines.